+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy



Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy



Leukemia and Lymphoma 21(1-2): 63-70



High-dose therapy followed by autografting can cure patients with aggressive Hodgkin's disease (HD) refractory or with early relapse to first-line combination chemotherapy. On the other hand, the eradication of the disease is rarely achieved in heavily pretreated patients. It has been suggested that patients with HD with very high risk characteristics at diagnosis, often relapse despite appropriate therapy with 7-8 drugs combination. Thus it seems to us that such patients are potential candidates for early autografting during first remission. Twelve years ago, we initiated a pilot study to investigate whether patients with very high risk characteristics, would benefit from early autografting. The application of early autografting was compared with our historical group of patients in complete remission after receiving MOPP/ABVD, who had the same negative prognostic characteristics, refused autografting and who did not receive other treatment after achieving complete remission. Among the 22 consecutive patients entered into the pilot study and autografted, 18 are alive and 17 (77%) remain alive in unmaintained remission at a median of 86 months. One patient (4%) died of interstitial pneumonitis in the transplantation group. Only 8/24 (33%) patients, who did not receive an autograft, are currently alive and disease free at a median of 89 months. In conclusion, the early application of autografting appears to improve the outcome in patients with very high risk HD who achieved remission with MOPP/ABVD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047852539

Download citation: RISBibTeXText

PMID: 8907271

DOI: 10.3109/10428199609067581


Related references

Twelve years experience with autografting for high-risk Hodgkins disease patients in first remission after Mopp/ABVD chemotherapy. British Journal of Haematology 93(Suppl. 2): 365, 1996

Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin's disease in first complete remission after MOPP/ABVD. Leukemia and Lymphoma 15(Suppl. 1): 59-61, 1995

Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplantation 8(2): 99, 1991

High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. Journal of Clinical Oncology 17(10): 3101-3109, 1999

High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients. Korean Journal of Internal Medicine 19(2): 114-120, 2004

High-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's lymphoma: a single center experience. Haematologica 86(12): 1317-1318, 2001

Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. British Journal of Haematology 118(1): 189-194, 2002

A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission. British Journal of Haematology 104(4): 763-769, 1999

Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse). Hematology/Oncology Clinics of North America 28(1): 75-86, 2014

Results of high dose chemotherapy and autologous stem cell transplantation in patients with high and intermediate grade lymphoma in first remission Stratification by international prognostic risk factors. Blood 96(11 Part 1): 794a, 2000

Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. Bone Marrow Transplantation 29(10): 833-842, 2002

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. British Journal of Cancer 81(3): 476-483, 1999

High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: The EBMT experience. Annals of Oncology 5(Suppl 2): S155-S159, 1994

High-dose therapy and autologous stem cell transplantation as consolidation therapy during first complete remission or partial remission in patients with unfavorable prognosis and advanced stage Hodgkins disease. Blood 90(10 Suppl. 1 Part 1): 114A, 1997

Phase I Study of Involved Field Radiation Therapy Preceding High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High Risk Hodgkins Disease and Non-Hodgkins Lymphoma. Blood 100(11): Abstract No 3405, 2002